Aflac inc(AFL.US AI Earnings Summary)
AFL AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
Earnings significantly beat expectations, with the stock up 0.75% on the first trading day after earnings; actuarial assumption releases and Japanese asset reallocation solidified long-term earnings momentum.
- Stock Reaction: AFLAC INC (AFL) delivered strong earnings and its 44th consecutive annual dividend increase; results were released after the U.S. market close on 11/4, and the stock closed at $126.24 on 11/5 (the first trading day after earnings), up 0.75% from the 11/4 close of $125.30.
- Market Expectations: Adjusted EPS of $2.43 was approximately 35.0% above the $1.80 TradingView pre-earnings market expectation, driven primarily by a $447M pre-tax gain from actuarial assumption releases (contributing $0.71 to EPS). On revenue, GAAP total revenues of $3.271B include roughly $1.1B of net investment losses and are not on the same basis as the TradingView revenue estimate, so no beat/miss comparison is made.
- Performance vs. Guidance: All targets were met or exceeded. Aflac Japan's Benefit Ratio was 49.2%, about 10.8 percentage points below the lower bound of guidance (60%–63%). Aflac Japan's expense ratio was 21.2%, falling in the middle of the guidance range (20%–23%). Aflac U.S. net earned premium growth was 3.3%, at the lower end of the guidance range (3%–6%).
- In a Nutshell: This quarter's adjusted EPS surged due to actuarial assumption releases and the results of asset restructuring in Japan; the stock closed up 0.75% at $126.24 on 11/5, the first trading day after earnings.
Quarterly Highlights
Adjusted EPS significantly exceeded market expectations, with actuarial assumption releases being the primary driver.
Adjusted EPS significantly higher than market expectations: Adjusted EPS (Non-GAAP) reached $2.43 this quarter, approximately 35% higher than the $1.80 TradingView pre-earnings market expectation. The main driver was a $447M pre-tax remeasurement gain from the annual third-quarter actuarial assumption review, contributing $0.71 per share.
Aflac Japan benefit ratio significantly below full-year expectations, pre-tax profit margin hits high: The Japan business benefit ratio was 49.2%, about 10.8 percentage points below the lower bound of the 60%–63% full-year target, mainly due to actuarial assumption releases and continued favorable trends in cancer-related hospitalization and mortality. Pre-tax profit margin reached 44.4%, leading management to raise the full-year 2026 Japan pre-tax profit margin expectation to 35%–38%.
Aflac U.S. high-speed growth across multiple lines, pre-tax margin far exceeds expectations: U.S. net earned premiums grew 3.3% year-over-year, at the lower end of guidance; however, group platform earned premiums grew 17% year-over-year, with Group Life and Disability (PLAD) up 29% and Dental and Vision (D&V) up 55%. Pre-tax profit margin reached 27.7%, above the upper limit of the 17%–20% full-year target range.
Japan internal reinsurance transaction releases approximately $1B in capital: This quarter, Aflac Japan transferred approximately 500 billion yen in cancer insurance reserves to Aflac Re Bermuda, increasing the Japan business transfer ratio from 10% to 15% (based on FSA statutory reserves). This is estimated to release approximately $1B in capital for reallocation over time, with significant room remaining before the 30% internal cap.
Portfolio switch trades continue to boost future net investment income: The company executed a $2.3B switch trade in Japanese government bonds this quarter, replacing low-yield old bonds with current high-yield assets, expected to boost future annualized net investment income by over $30M. CFO Max Brodén noted that year-to-date active management has added over $80M to annualized net investment income.
Robust shareholder returns, 44 consecutive years of dividend increases: Total shareholder returns this quarter amounted to $1.109B, including $804M in share repurchases and $305M in cash dividends. Cumulative returns for the first three quarters reached $3.7B. CEO Dan Amos emphasized the milestone of 44 consecutive years of dividend increases in 2026.
Actuarial assumption releases will continue to lower future benefit ratios: CFO Max Brodén confirmed that the assumption updates lowered the future net premium ratio for Japan by 70 bps, the U.S. by 60 bps, and Aflac Re Bermuda by 320 bps, which is expected to have a sustained positive impact on benefit ratios in Q4 and subsequent quarters.
Tsumitasu accounts for 20% of sales, effectively driving third-sector cross-selling: Aflac Japan sales head Yoshizumi stated that Tsumitasu currently accounts for about 20% of total sales in Japan, successfully attracting younger and middle-aged new customers while driving simultaneous sales of cancer and medical insurance. The actual cross-selling ratio has significantly exceeded the original 25% target.